JP2013540102A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013540102A5 JP2013540102A5 JP2013516609A JP2013516609A JP2013540102A5 JP 2013540102 A5 JP2013540102 A5 JP 2013540102A5 JP 2013516609 A JP2013516609 A JP 2013516609A JP 2013516609 A JP2013516609 A JP 2013516609A JP 2013540102 A5 JP2013540102 A5 JP 2013540102A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- methyl
- cycloalkyl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 287
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 30
- 239000000651 prodrug Substances 0.000 claims 28
- 229940002612 prodrugs Drugs 0.000 claims 28
- 229910052739 hydrogen Inorganic materials 0.000 claims 23
- 125000003118 aryl group Chemical group 0.000 claims 21
- 125000001072 heteroaryl group Chemical group 0.000 claims 18
- 239000004471 Glycine Substances 0.000 claims 16
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 125000003342 alkenyl group Chemical group 0.000 claims 14
- 125000004429 atoms Chemical group 0.000 claims 13
- 229910052799 carbon Inorganic materials 0.000 claims 13
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 12
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 125000005842 heteroatoms Chemical group 0.000 claims 12
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 12
- 229910052717 sulfur Inorganic materials 0.000 claims 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 125000003277 amino group Chemical group 0.000 claims 9
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 7
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 7
- 239000004472 Lysine Substances 0.000 claims 7
- 235000004279 alanine Nutrition 0.000 claims 7
- 235000018417 cysteine Nutrition 0.000 claims 7
- 235000018977 lysine Nutrition 0.000 claims 7
- 125000001963 4 membered heterocyclic group Chemical group 0.000 claims 6
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 6
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 6
- 239000004475 Arginine Substances 0.000 claims 6
- 229960001230 Asparagine Drugs 0.000 claims 6
- 229960005261 Aspartic Acid Drugs 0.000 claims 6
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims 6
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims 6
- 229960002989 Glutamic Acid Drugs 0.000 claims 6
- 229960000310 ISOLEUCINE Drugs 0.000 claims 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 6
- 229960005190 Phenylalanine Drugs 0.000 claims 6
- 239000004473 Threonine Substances 0.000 claims 6
- 125000001931 aliphatic group Chemical group 0.000 claims 6
- 235000009582 asparagine Nutrition 0.000 claims 6
- 235000003704 aspartic acid Nutrition 0.000 claims 6
- 235000013922 glutamic acid Nutrition 0.000 claims 6
- 239000004220 glutamic acid Substances 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 229920000728 polyester Polymers 0.000 claims 6
- 239000004474 valine Substances 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 3
- 150000001413 amino acids Chemical group 0.000 claims 3
- DTHNMHAUYICORS-KTKZVXAJSA-N 107444-51-9 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 2
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 125000005354 acylalkyl group Chemical group 0.000 claims 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 102100003818 GCG Human genes 0.000 claims 1
- 101710042131 GCG Proteins 0.000 claims 1
- 101700071595 GRZ1 Proteins 0.000 claims 1
- 229960004666 Glucagon Drugs 0.000 claims 1
- 108060003199 Glucagon Proteins 0.000 claims 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N Glucagonum Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 1
- 230000036499 Half live Effects 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 101700078733 ZGLP1 Proteins 0.000 claims 1
- KZNQNBZMBZJQJO-YFKPBYRVSA-N gly pro Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 claims 1
- 108010077515 glycylproline Proteins 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000004962 physiological condition Effects 0.000 claims 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N α-aminoisobutanoic acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35818810P | 2010-06-24 | 2010-06-24 | |
| US61/358,188 | 2010-06-24 | ||
| PCT/US2011/040330 WO2011163012A2 (fr) | 2010-06-24 | 2011-06-14 | Promédicaments peptidiques à base d'amides de la superfamille du glucagon |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013540102A JP2013540102A (ja) | 2013-10-31 |
| JP2013540102A5 true JP2013540102A5 (fr) | 2014-07-31 |
Family
ID=45372025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013516609A Pending JP2013540102A (ja) | 2010-06-24 | 2011-06-14 | アミド結合を介して修飾されたグルカゴンスーパーファミリーのペプチドプロドラッグ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8778872B2 (fr) |
| EP (1) | EP2588126A4 (fr) |
| JP (1) | JP2013540102A (fr) |
| KR (1) | KR20130102470A (fr) |
| CN (1) | CN103179979A (fr) |
| AR (1) | AR081471A1 (fr) |
| CA (1) | CA2796894A1 (fr) |
| MX (1) | MX2012014576A (fr) |
| RU (1) | RU2580317C2 (fr) |
| TW (1) | TW201209062A (fr) |
| WO (1) | WO2011163012A2 (fr) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007056362A2 (fr) | 2005-11-07 | 2007-05-18 | Indiana University Research And Technology Corporation | Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees |
| EP2487184A1 (fr) | 2007-02-15 | 2012-08-15 | Indiana University Research and Technology Corporation | Co-agonistes du récepteur de glucagon/GLP-1 |
| JP5631201B2 (ja) | 2007-03-28 | 2014-11-26 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ステッチングされたポリペプチド |
| ES2509883T3 (es) | 2007-10-30 | 2014-10-20 | Indiana University Research And Technology Corporation | Antagonistas de glucagón |
| ES2558155T3 (es) | 2007-10-30 | 2016-02-02 | Indiana University Research And Technology Corporation | Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1 |
| AU2009210570B2 (en) | 2008-01-30 | 2014-11-20 | Indiana University Research And Technology Corporation | Ester-based insulin prodrugs |
| US9062124B2 (en) | 2008-06-17 | 2015-06-23 | Indiana University Research And Technology Corporation | GIP-based mixed agonists for treatment of metabolic disorders and obesity |
| CL2009001424A1 (es) | 2008-06-17 | 2010-04-30 | Univ Indiana Res & Tech Corp | Peptido tipo glucagon; dimero que comprende dos de dichos peptidos; composicion farmaceutica que lo comprende; y su uso para tratar diabetes o inducir perdida de peso. |
| EP2376097A4 (fr) | 2008-12-19 | 2012-10-03 | Univ Indiana Res & Tech Corp | Promédicaments peptidiques de la superfamille du glucagon à base d'amide |
| CA2747490C (fr) | 2008-12-19 | 2017-02-14 | Indiana University Research And Technology Corporation | Analogues d'insuline |
| WO2010080609A1 (fr) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Promédicaments insuliniques à base d'amide |
| CA2765026A1 (fr) | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Composes de glucagon actifs sur le recepteur gip |
| BR112012018585A2 (pt) | 2010-01-27 | 2017-01-10 | Univ Indiana Res & Tech Corp | conjungados e composições de glucagon antagonista-gip agonista para o tratamento de distúrbios metabólicos e de obesidade |
| US9127088B2 (en) | 2010-05-13 | 2015-09-08 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
| BR112012028707A2 (pt) | 2010-05-13 | 2019-09-24 | Univ Indiana Res & Tech Corp | composto de glucagon da superfamília de peptídeos exibindo atividade do receptor g com proteína acoplada, pró farmaco, dímero ou multímro, composição farmacêutica que o compreendem e método de administração do mesmo. |
| EP2582719B1 (fr) | 2010-06-16 | 2016-08-10 | Indiana University Research and Technology Corporation | Agonistes de l'insuline à une seule chaîne très actifs au niveau du récepteur à l'insuline |
| CN103119057B (zh) | 2010-06-24 | 2016-06-15 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰岛素前药 |
| PT2603600T (pt) | 2010-08-13 | 2019-02-27 | Aileron Therapeutics Inc | Macrociclos peptidomiméticos |
| EA201390941A1 (ru) | 2010-12-22 | 2013-12-30 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Аналоги глюкагона, проявляющие активность на рецепторе gip |
| SG10201604564XA (en) | 2011-06-10 | 2016-07-28 | Hanmi Science Co Ltd | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
| AU2012270366C1 (en) | 2011-06-17 | 2017-07-13 | Hanmi Science Co., Ltd. | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
| CA2839867A1 (fr) | 2011-06-22 | 2012-12-27 | Indiana University Research And Technology Corporation | Co-agonistes du recepteur du glucagon et du recepteur du gpl-1 |
| RS56173B1 (sr) | 2011-06-22 | 2017-11-30 | Univ Indiana Res & Tech Corp | Koagonisti receptora za glukagon/glp-1 receptora |
| TWI643868B (zh) | 2011-10-18 | 2018-12-11 | 艾利倫治療公司 | 擬肽巨環化合物 |
| JP6324315B2 (ja) | 2011-11-17 | 2018-05-16 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド |
| CN104114183A (zh) | 2011-12-20 | 2014-10-22 | 印第安纳大学研究及科技有限公司 | 用于治疗糖尿病的基于ctp的胰岛素类似物 |
| CN104144695A (zh) | 2012-02-15 | 2014-11-12 | 爱勒让治疗公司 | 三唑交联的和硫醚交联的拟肽大环化合物 |
| AR089993A1 (es) | 2012-02-15 | 2014-10-01 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos |
| EP2820038B1 (fr) * | 2012-03-01 | 2020-06-17 | Novo Nordisk A/S | Promédicaments glp-1 |
| US9404108B2 (en) * | 2012-03-04 | 2016-08-02 | Bonac Corporation | Micro-RMA inhibitor |
| RU2015101697A (ru) | 2012-06-21 | 2016-08-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Аналоги глюкагона, обладающие активностью рецептора gip |
| MY185217A (en) * | 2012-06-21 | 2021-04-30 | Hoffmann La Roche | Analogs of glucagon exhibiting gip receptor activity |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| CA2886228A1 (fr) | 2012-09-26 | 2014-04-03 | Indiana University Research And Technology Corporation | Dimeres analogues de l'insuline |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| MX2015005244A (es) | 2012-11-01 | 2015-07-14 | Aileron Therapeutics Inc | Aminoacidos disustituidos y metodos de preparacion y el uso de los mismos. |
| KR102311517B1 (ko) | 2012-11-06 | 2021-10-14 | 한미약품 주식회사 | 옥신토모듈린과 면역글로불린 단편을 포함하는 단백질 결합체의 액상 제제 |
| KR101993393B1 (ko) * | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| ES2653765T3 (es) | 2012-12-21 | 2018-02-08 | Sanofi | Agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón |
| CA2904332A1 (fr) | 2013-03-14 | 2014-10-02 | Indiana University Research And Technology Corporation | Conjugues d'insuline-incretine |
| WO2014152460A2 (fr) * | 2013-03-15 | 2014-09-25 | Indiana University Research And Technology Corporation | Promédicaments et une action prolongée |
| US9907856B2 (en) | 2013-07-08 | 2018-03-06 | The Regents Of The University Of California | Carboxymethylcellulose-peptide conjugates and methods for using the same |
| WO2015035419A1 (fr) * | 2013-09-09 | 2015-03-12 | Hoffmann-La Roche Inc. | Doses de peptides co-agonistes de gip/glp-1 pour l'administration auxhumains |
| EP3077008B1 (fr) | 2013-12-06 | 2023-10-04 | Jie Han | Pro-fragments bioréversibles pour médicaments contenant de l'azote et de l'hydroxyle |
| WO2015086729A1 (fr) | 2013-12-13 | 2015-06-18 | Sanofi | Agonistes mixtes des récepteurs glp-1/gip |
| EP3080149A1 (fr) | 2013-12-13 | 2016-10-19 | Sanofi | Agonistes mixtes des récepteurs du glp-1/glucagon |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| AR098616A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| GB2528436A (en) * | 2014-07-15 | 2016-01-27 | Lancaster Univ Business Entpr Ltd | Treatment of neurological diseases |
| TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| KR20170058424A (ko) | 2014-09-24 | 2017-05-26 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방 거대고리 및 이의 용도 |
| ES2947409T3 (es) | 2014-09-24 | 2023-08-08 | Univ Indiana Res & Tech Corp | Profármacos de insulina a base de amida lipídica |
| EP3206710B1 (fr) | 2014-09-24 | 2020-05-06 | Indiana University Research & Technology Corporation | Conjugués d'insuline-incrétines |
| KR101996739B1 (ko) | 2014-10-24 | 2019-10-01 | 머크 샤프 앤드 돔 코포레이션 | 글루카곤 및 glp-1 수용체의 공-효능제 |
| KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| US10253067B2 (en) | 2015-03-20 | 2019-04-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| WO2018009778A1 (fr) * | 2016-07-07 | 2018-01-11 | Baylor College Of Medicine | Combinaison de glp-1 et de glp-2 pour le traitement ou la prévention de maladies, troubles et syndromes métaboliques |
| EP3852786A4 (fr) * | 2018-09-19 | 2022-09-28 | Georgia Tech Research Corporation | Promédicament activé par protéase bactérienne à auto-dosage |
| WO2021083306A1 (fr) * | 2019-10-31 | 2021-05-06 | 东莞市东阳光生物药研发有限公司 | Polypeptide agoniste double accepteur de glp-1/gcg |
| CN115697414A (zh) * | 2020-06-03 | 2023-02-03 | 哥本哈根大学 | Glp1r激动剂nmdar拮抗剂缀合物 |
| US20220177538A1 (en) | 2020-07-22 | 2022-06-09 | Novo Nordisk A/S | Co-agonists at glp-1 and gip receptors suitable for oral delivery |
| KR20230104118A (ko) | 2020-11-06 | 2023-07-07 | 노보 노르디스크 에이/에스 | Glp-1 전구약물 및 이의 용도 |
| WO2023012263A1 (fr) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Formulations solides de peptides oraux |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| TW202346324A (zh) | 2022-05-10 | 2023-12-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| CN114636773B (zh) * | 2022-05-23 | 2022-08-23 | 广东国标医药科技有限公司 | 一种药用辅料中聚乙二醇单甲醚2000的含量测定方法 |
| WO2024110614A1 (fr) | 2022-11-25 | 2024-05-30 | Novo Nordisk A/S | Administration orale d'agents thérapeutiques peptidiques, tels que glp-1 |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US171920A (en) | 1876-01-11 | Improvement in hat and coat hooks | ||
| US3740385A (en) | 1970-05-07 | 1973-06-19 | M Ondetti | N-terminal derivatives of secretin |
| US4275152A (en) | 1977-02-03 | 1981-06-23 | Eastman Kodak Company | Hydrolysis of protein-bound cholesterol esters |
| PT83613B (en) | 1985-10-28 | 1988-11-21 | Lilly Co Eli | Process for the selective chemical removal of a protein amino-terminal residue |
| EP0272253A4 (fr) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | Procede pour ameliorer la stabilite des glycoproteines. |
| US4741897A (en) | 1986-07-08 | 1988-05-03 | Baxter Travenol | Thyroxine analogs and reagents for thyroid hormone assays |
| ATE123780T1 (de) | 1989-02-17 | 1995-06-15 | Chiron Mimotopes Pty Ltd | Verfahren zur verwendung und herstellung von peptiden. |
| JP3262329B2 (ja) | 1990-01-24 | 2002-03-04 | アイ． バックレイ，ダグラス | 糖尿病治療に有用なｇｌｐ―１アナログ |
| CA2024855C (fr) | 1990-09-07 | 1997-12-09 | Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee | Procede et intermediaires pour la production du glucagon |
| JPH04145099A (ja) | 1990-10-05 | 1992-05-19 | Sanwa Kagaku Kenkyusho Co Ltd | Ｇｉｐ様活性を有するポリペプチド誘導体及びその用途 |
| US5510459A (en) | 1991-01-17 | 1996-04-23 | Zymogenetics, Inc. | Glucagon antagonists |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5480867A (en) | 1993-12-29 | 1996-01-02 | The Rockefeller University | Glucagon analogs with serine replacements |
| US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| US5691309A (en) | 1995-01-31 | 1997-11-25 | Eli Lilly And Company | Anti-obesity proteins |
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| DE19530865A1 (de) | 1995-08-22 | 1997-02-27 | Michael Dr Med Nauck | Wirkstoff sowie Mittel zur parenteralen Ernährung |
| IL121070A (en) | 1995-10-12 | 2004-06-20 | Supergen Inc | LIPOSOME FORMULATIONS OF 5beta STEROIDS |
| US6180767B1 (en) | 1996-01-11 | 2001-01-30 | Thomas Jefferson University | Peptide nucleic acid conjugates |
| AU2263197A (en) | 1996-02-06 | 1997-08-28 | Eli Lilly And Company | Diabetes therapy |
| IL128828A0 (en) | 1996-09-09 | 2000-01-31 | Zealand Pharmaceuticals As | Peptide prodrugs containing an alpha-hydroxy acid linker |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| AU5518798A (en) | 1996-12-03 | 1998-06-29 | Trustees Of Boston University | Specific antagonists for glucose-dependent insulinotropic polypeptide (gip) |
| EP1062229A1 (fr) | 1998-03-09 | 2000-12-27 | Zealand Pharmaceuticals A/S | Conjugues peptidiques pharmacologiquement actifs ayant une tendance reduite a l'hydrolyse enzymatique |
| DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
| US20030236190A1 (en) | 1998-09-02 | 2003-12-25 | Renuka Pillutla | Isulin and IGF-1 receptor agonists and antagonists |
| DE69926007T2 (de) | 1998-10-07 | 2005-12-29 | Medical College Of Georgia Research Institute, Inc. | Glukose-abhängiges, insulinotropisches peptid für die verwendung als osteotropes hormon |
| CZ303399B6 (cs) * | 1998-12-07 | 2012-08-29 | Ipsen Pharma S.A.S. | Peptidový analog GLP-1 a farmaceutický prostredek jej obsahující |
| JP2002534512A (ja) | 1999-01-15 | 2002-10-15 | ノボ ノルディスク アクティーゼルスカブ | 非ペプチドｇｌｐ−１アゴニスト |
| DE60012721T4 (de) | 1999-03-29 | 2010-09-09 | Uutech Ltd., Coleraine | Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes |
| US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
| AUPQ661800A0 (en) | 2000-03-31 | 2000-05-04 | Metabolic Pharmaceuticals Limited | Insulin-potentiating compounds |
| CA2405900A1 (fr) | 2000-04-27 | 2001-11-01 | Bionebraska, Inc. | Test de diagnostic de polypeptide inhibiteur gastrique destine a la detection de la sensibilite aux diabetes de type 2, a une intolerance au glucose, ou a une glycemie a jeun |
| US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| WO2001096368A2 (fr) | 2000-06-14 | 2001-12-20 | Cytovax Biotechnologies, Inc. | Utilisation d'un echafaudage structural a superhelice afin de generer des peptides specifiques de structure |
| SI1695983T1 (sl) | 2000-06-16 | 2009-08-31 | Lilly Co Eli | Analogi glukagonu podobnega peptida-1 |
| CA2417100A1 (fr) | 2000-08-02 | 2002-02-07 | Theratechnologies Inc. | Peptides biologiques modifies presentant une activite renforcee |
| WO2002012201A1 (fr) | 2000-08-04 | 2002-02-14 | Dmi Biosciences, Inc. | Procédé de synthétisation de dikétopiperazines |
| US6262062B1 (en) | 2000-08-15 | 2001-07-17 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US20020045572A1 (en) | 2000-08-15 | 2002-04-18 | Cpd, Llc | Method of treating the syndrome of type 2 diabetes in humans |
| US6528520B2 (en) | 2000-08-15 | 2003-03-04 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| ES2367891T3 (es) | 2000-09-29 | 2011-11-10 | Schering Corporation | Interleucina-10 pegilada. |
| US7199217B2 (en) | 2000-12-13 | 2007-04-03 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
| EP1243276A1 (fr) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Prodrogues activables à séparateurs allongés et multiples |
| EP1456360B1 (fr) | 2001-04-19 | 2015-06-03 | The Scripps Research Institute | Procedes et compositions permettant la production de paires orthogonales de synthethases trna et de synthetases aminoacyl-trna |
| EP2275117B1 (fr) | 2001-07-31 | 2016-10-26 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | GLP-1, exendine-4, analogues de peptides et utilisations associées |
| US20040002468A1 (en) | 2001-08-08 | 2004-01-01 | Genzyme Corporation | Methods of treating diabetes and other blood sugar disorders |
| HUP0501192A3 (en) | 2001-08-23 | 2006-06-28 | Lilly Co Eli | Glucagon-like peptide-1 analogs |
| CN1635900A (zh) | 2001-08-28 | 2005-07-06 | 伊莱利利公司 | Glp－1和基础胰岛素的预混合物 |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| US7041646B2 (en) | 2001-10-05 | 2006-05-09 | Bayer Pharmaceuticals Corporation | Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists |
| AR036711A1 (es) | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
| US7238671B2 (en) * | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| MXPA04003553A (es) | 2001-10-18 | 2004-07-22 | Bristol Myers Squibb Co | Mimeticos del peptido-1 similares aglucagon humano y su uso en tratamiento de diabetes y condiciones relacionadas. |
| MXPA04003569A (es) | 2001-10-19 | 2004-07-23 | Lilly Co Eli | Mezclas bifasicas de glp-1 e insulina. |
| KR20040070237A (ko) | 2001-12-20 | 2004-08-06 | 일라이 릴리 앤드 캄파니 | 연장된 작용 시간을 갖는 인슐린 분자 |
| WO2003059378A2 (fr) | 2001-12-29 | 2003-07-24 | Novo Nordisk A/S | Utilisation combinee d'un compose glp-1 et d'un autre medicament pour traiter la dyslipidemie |
| AR038102A1 (es) | 2002-01-08 | 2004-12-29 | Lilly Co Eli | Analogos extendidos de peptido 1 de tipo glucagon |
| US20030232761A1 (en) | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
| EP1575490A4 (fr) | 2002-06-04 | 2007-08-08 | Lilly Co Eli | Analogues modifies du peptide-1 de type glucagon (glp-1) |
| FR2842209B1 (fr) | 2002-07-09 | 2007-11-23 | Nouvelle protease aspartique dite saspase et son utilisation dans le domaine cosmetique et therapeutique | |
| EP1539210A4 (fr) | 2002-09-06 | 2006-06-07 | Bayer Pharmaceuticals Corp | Agonistes modifies du recepteur glp-1 et leurs procedes pharmacologiques d'utilisation |
| US7192922B2 (en) | 2002-11-19 | 2007-03-20 | Allegheny-Singer Research Institute | Method of treating left ventricular dysfunction |
| AU2004204494B2 (en) | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| WO2004067548A2 (fr) | 2003-01-31 | 2004-08-12 | Theratechnologies Inc. | Metabolites chimiquement modifies de peptides regulateurs et methodes de production et d'utilisation associees |
| PT1605897E (pt) | 2003-03-19 | 2012-09-10 | Lilly Co Eli | Compostos de glp-1 ligado a polietilenoglicol |
| EP1620118B1 (fr) | 2003-04-08 | 2014-06-18 | Yeda Research And Development Co., Ltd. | Medicaments pegyles reversibles |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| JP2007524592A (ja) | 2003-06-03 | 2007-08-30 | ノボ・ノルデイスク・エー／エス | 安定化された薬学的ペプチド組成物 |
| WO2004105781A2 (fr) | 2003-06-03 | 2004-12-09 | Novo Nordisk A/S | Compositions pharmaceutiques peptidiques stabilisees |
| SI1641823T1 (sl) | 2003-06-12 | 2011-12-30 | Lilly Co Eli | Fuzijski proteini analogni glp-1 |
| WO2004111078A2 (fr) | 2003-06-18 | 2004-12-23 | Theratechnologies Inc. | Composes qui modulent la reponse du glucagon et utilisations associees |
| SI2932981T1 (sl) | 2003-09-19 | 2021-11-30 | Novo Nordisk A/S | Albumin-vezavni derivati GLP-1 |
| US20050187147A1 (en) | 2003-09-22 | 2005-08-25 | Newman Michael J. | Compositions and methods for increasing drug efficiency |
| US7364875B2 (en) | 2003-10-30 | 2008-04-29 | Cresent Innovations, Inc. | Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight |
| EP1704165B1 (fr) | 2003-12-18 | 2010-03-17 | Novo Nordisk A/S | Composes de glp-1 |
| US20060286129A1 (en) | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
| US20080318837A1 (en) | 2003-12-26 | 2008-12-25 | Nastech Pharmaceutical Company Inc. | Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide |
| EA200701362A1 (ru) | 2004-12-22 | 2008-08-29 | Сентокор, Инк. | Агонисты glp-1, композиции, способы и применения |
| US20090286723A1 (en) | 2005-02-11 | 2009-11-19 | Amylin Pharmaceuticals, Inc. | Hybrid Polypeptides with Selectable Properties |
| KR20070115947A (ko) | 2005-02-11 | 2007-12-06 | 아밀린 파마슈티칼스, 인크. | 선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드 |
| JP2008533104A (ja) | 2005-03-18 | 2008-08-21 | ノボ ノルディスク アクティーゼルスカブ | Ｇｌｐ−１受容体の二量体ペプチドアゴニスト |
| WO2006124529A1 (fr) | 2005-05-13 | 2006-11-23 | Eli Lilly And Company | Composes glp-1 pegyles |
| BRPI0612069A2 (pt) | 2005-06-13 | 2009-01-20 | Imp Innovations Ltd | compostos e seus efeitos sobre o comportamento de alimentaÇço |
| EP2497781A1 (fr) | 2005-09-08 | 2012-09-12 | Trustees Of Tufts College | Analogues de GLP-1 stabilisés |
| US7846445B2 (en) | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
| WO2007056362A2 (fr) | 2005-11-07 | 2007-05-18 | Indiana University Research And Technology Corporation | Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees |
| US7928058B2 (en) | 2006-02-22 | 2011-04-19 | Merck Sharp & Dohme Corp. | Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition |
| WO2007104786A1 (fr) | 2006-03-15 | 2007-09-20 | Novo Nordisk A/S | Melanges d'amyline et d'insuline |
| CA2646598C (fr) * | 2006-03-21 | 2014-08-19 | Amylin Pharmaceuticals, Inc. | Conjugues inhibiteur de peptidase-peptide et procedes d'utilisation de ceux-ci |
| WO2007124461A2 (fr) | 2006-04-20 | 2007-11-01 | Amgen Inc. | Composés de glp-1 |
| US20090318353A1 (en) | 2006-08-25 | 2009-12-24 | Novo Nordisk A/S | Acylated Exendin-4 Compounds |
| DK2615108T3 (en) | 2006-09-08 | 2017-01-30 | Ambrx Inc | Modified human plasma polypeptide or fc scaffolds and their applications |
| US8669228B2 (en) | 2007-01-05 | 2014-03-11 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological pH buffers |
| EP2487184A1 (fr) | 2007-02-15 | 2012-08-15 | Indiana University Research and Technology Corporation | Co-agonistes du récepteur de glucagon/GLP-1 |
| EP2185701A4 (fr) | 2007-08-15 | 2011-03-02 | Amunix Operating Inc | Compositions et procédés d'amélioration de la production de polypeptides recombinés |
| ES2550363T3 (es) | 2007-09-05 | 2015-11-06 | Novo Nordisk A/S | Derivados truncados de GLP-1 y su uso terapéutico |
| CN101868476B (zh) | 2007-09-05 | 2015-02-25 | 诺沃-诺迪斯克有限公司 | 胰高血糖素样肽-1衍生物及其制药用途 |
| EP2650006A1 (fr) | 2007-09-07 | 2013-10-16 | Ipsen Pharma S.A.S. | Analogues d'exendine-4 et exendine-3 |
| GB0717399D0 (en) * | 2007-09-07 | 2007-10-17 | Uutech Ltd | Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission |
| EP2036539A1 (fr) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Formulations stables d'amyline et ses analogues |
| EP2036923A1 (fr) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Dérivés d'amyline améliorés |
| EP2200635A1 (fr) | 2007-09-11 | 2010-06-30 | Novo Nordisk A/S | Mélange comprenant de l'amyline, qui est un peptide, et une insuline retard |
| ES2558155T3 (es) | 2007-10-30 | 2016-02-02 | Indiana University Research And Technology Corporation | Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1 |
| ES2509883T3 (es) | 2007-10-30 | 2014-10-20 | Indiana University Research And Technology Corporation | Antagonistas de glucagón |
| AU2009210570B2 (en) | 2008-01-30 | 2014-11-20 | Indiana University Research And Technology Corporation | Ester-based insulin prodrugs |
| EP2237799B1 (fr) * | 2008-02-01 | 2019-04-10 | Ascendis Pharma A/S | Promédicament comprenant un linker auto-clivable |
| AU2009260301B2 (en) | 2008-06-17 | 2015-09-03 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers |
| CL2009001424A1 (es) | 2008-06-17 | 2010-04-30 | Univ Indiana Res & Tech Corp | Peptido tipo glucagon; dimero que comprende dos de dichos peptidos; composicion farmaceutica que lo comprende; y su uso para tratar diabetes o inducir perdida de peso. |
| US9062124B2 (en) | 2008-06-17 | 2015-06-23 | Indiana University Research And Technology Corporation | GIP-based mixed agonists for treatment of metabolic disorders and obesity |
| US20110237493A1 (en) | 2008-12-19 | 2011-09-29 | Indiana University Research And Technology Corporation | Dipeptide linked medicinal agents |
| EP2376097A4 (fr) | 2008-12-19 | 2012-10-03 | Univ Indiana Res & Tech Corp | Promédicaments peptidiques de la superfamille du glucagon à base d'amide |
| WO2010096052A1 (fr) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Analogues d'oxyntomoduline |
| CA2765026A1 (fr) | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Composes de glucagon actifs sur le recepteur gip |
| US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| BR112012018585A2 (pt) | 2010-01-27 | 2017-01-10 | Univ Indiana Res & Tech Corp | conjungados e composições de glucagon antagonista-gip agonista para o tratamento de distúrbios metabólicos e de obesidade |
| AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| BR112012028707A2 (pt) | 2010-05-13 | 2019-09-24 | Univ Indiana Res & Tech Corp | composto de glucagon da superfamília de peptídeos exibindo atividade do receptor g com proteína acoplada, pró farmaco, dímero ou multímro, composição farmacêutica que o compreendem e método de administração do mesmo. |
| US9127088B2 (en) | 2010-05-13 | 2015-09-08 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
| WO2011163473A1 (fr) | 2010-06-25 | 2011-12-29 | Indiana University Research And Technology Corporation | Analogues du glucagon présentant une solubilité et une stabilité améliorées dans des tampons à ph physiologique |
-
2011
- 2011-06-14 MX MX2012014576A patent/MX2012014576A/es not_active Application Discontinuation
- 2011-06-14 EP EP11798640.6A patent/EP2588126A4/fr not_active Withdrawn
- 2011-06-14 KR KR1020127033177A patent/KR20130102470A/ko not_active Application Discontinuation
- 2011-06-14 CA CA2796894A patent/CA2796894A1/fr not_active Abandoned
- 2011-06-14 RU RU2013103093/04A patent/RU2580317C2/ru not_active IP Right Cessation
- 2011-06-14 CN CN201180031415XA patent/CN103179979A/zh active Pending
- 2011-06-14 WO PCT/US2011/040330 patent/WO2011163012A2/fr active Application Filing
- 2011-06-14 JP JP2013516609A patent/JP2013540102A/ja active Pending
- 2011-06-14 US US13/697,021 patent/US8778872B2/en active Active
- 2011-06-23 TW TW100121933A patent/TW201209062A/zh unknown
- 2011-06-23 AR ARP110102184A patent/AR081471A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013540102A5 (fr) | ||
| RU2013103093A (ru) | Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкаганов | |
| RU2013102991A (ru) | Связанные с дипептидом лекарственные средства | |
| JP2013531659A5 (fr) | ||
| JP2012512901A5 (fr) | ||
| JP2017534675A5 (fr) | ||
| JP2013533864A5 (fr) | ||
| RU2010101232A (ru) | Производное инсулинотропного пептида, содержащее модифицированную n-концевую аминокислоту | |
| MX2020004912A (es) | Compuestos derivados de prostaciclinas, y el uso de los mismo para el tratamiento de la hipertension pulmonar. | |
| JP2016505586A5 (fr) | ||
| JP2012512898A5 (fr) | ||
| JP2011511778A5 (fr) | ||
| RU2014148530A (ru) | Производные дипептида лизин-глутаминовая кислота | |
| JP2010521485A5 (fr) | ||
| JP2014518546A5 (fr) | ||
| JP2017528467A5 (fr) | ||
| JP2013511554A5 (fr) | ||
| JP2013537907A5 (fr) | ||
| JP2004537581A5 (fr) | ||
| CA2604962A1 (fr) | Compositions de soins personnels | |
| JP2011511753A5 (fr) | ||
| JP2017503777A5 (fr) | ||
| JP2007500747A5 (fr) | ||
| CA2536182A1 (fr) | Peptides macrocycliques actifs contre le virus de l'hepatite c | |
| JP2016527277A5 (fr) |